Patient Education
Share your love
The Art and Science of Presbyopia Correction: Navigating the IOL Patient Journey | Ophthalmology Times
Presbyopia-correcting IOLs have undergone a dramatic transformation in recent years. The once-limited options for patients seeking reduced spectacle dependence after cataract surgery have evolved into a diverse and sophisticated array of IOL technologies, including trifocal, extended depth-of-focus (EDOF), small-aperture, light-adjustable,…
EYDENZELT, Celltrion’s biosimilar referencing EYLEA, approved in Canada | Ophthalmology Times
(Image Credit: AdobeStock/platinumArt) Health Canada has approved Celltrion’s Eydenzelt, a biosimilar referencing Eylea (aflibercept 2 mg), in both vial and pre-filled syringe format, for the treatment of all indications approved for Eylea, which in the US include neovascular (wet) age-related…
Prevent Blindness delegates first week of December as 5th annual geographic atrophy week | Ophthalmology Times
(Image Credit: AdobeStock/Marina April) Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the public and raise awareness. The Cleveland Clinic states that more than 8 million people in the…
Q&A: As DMEI turns 50, R. Michael Siatkowski, MD, MBA, looks to the future | Ophthalmology Times
R. Michael Siatkowski, MD, MBA, reflects on 50 years of innovation, research, and patient care at the Dean McGee Eye Institute and shares his vision for the future of ophthalmology. (Courtesy of Dean McGee Eye Institute) As Dean McGee Eye…
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined | Ophthalmology Times
(Image Credit: AdobeStock/Pixel-Shot) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 delivered major insights into anterior segment innovation, spanning corneal cross-linking care, refractive surgery evolution, and energy-based aesthetic technology. Presentations from Reena Gupta, MD; Arjan…
Clinical Experience and Integration of New Dry Eye Disease Therapies in the Clinic | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Managing Unique Dry Eye Disease Subtypes in Patients | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision | Ophthalmology Times
(Image Credit: AdobeStock/andrew_shots) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 showcased a powerful convergence of innovation in glaucoma care, emphasizing safer long-term pressure control, improved visualization technologies, and more individualized lens decision-making for complex…
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081 | Ophthalmology Times
(Image Credit: AdobeStock/Who is Danny) AAVantgarde and AGC Biologics have entered into an agreement in which AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s dual-vector gene therapies for inherited retinal disorders, AAVB-039 and AAVB-081.1 Most recently, AAVantgarde Bio…
Ocular Therapeutix randomizes first patient in HELIOS-3 | Ophthalmology Times
(Image Credit: AdobeStock/ronstik) Ocular Therapeutix has randomized the first patient in its HELIOS-3 phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR). The company describes AXPAXLI as an investigational, bioresorbable, intravitreal hydrogel incorporating…